aTYR PHARMA INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
aTYR PHARMA INC (ATYR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.51 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-05
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $2.51, a 116.38% increase from fiscal 2024.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.16, a 27.04% decline from fiscal 2023.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.59, a 36.14% decline from fiscal 2022.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.49, a 34.82% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.51 10-K · filed 2026-03-05 | |
| 2024-12-31 | $1.16 10-K · filed 2026-03-05 | |
| 2023-12-31 | $1.59 10-K · filed 2026-03-05 | |
| 2022-12-31 | $2.49 10-K · filed 2025-03-13 | |
| 2021-12-31 | $3.82 10-K · filed 2024-03-14 | |
| 2020-12-31 | $3.39 10-K · filed 2023-03-14 | |
| 2019-12-31 | $5.67 10-K · filed 2022-03-15 | |
| 2018-12-31 | $25.76 10-K · filed 2021-03-24 | $1.84 10-K · filed 2019-03-26 |
| 2017-12-31 | $39.95 10-K · filed 2020-03-26 | $2.85 10-K · filed 2018-03-20 |
| 2016-12-31 | $3.34 10-K · filed 2019-03-26 | |
| 2015-12-31 | $11.29 10-K · filed 2018-03-20 | |
| 2014-12-31 | $10.18 10-K · filed 2017-03-16 | |
| 2013-12-31 | $3.42 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |